![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-demecolcine | increases expression | ISO | RGD:735674 | 6480464 | Demecolcine results in increased expression of B3GNT5 mRNA | CTD | PMID:23649840 | 17beta-estradiol | decreases expression | ISO | RGD:735674 | 6480464 | Estradiol results in decreased expression of B3GNT5 mRNA | CTD | PMID:19167446, PMID:31614463 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:735674 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of B3GNT5 mRNA | CTD | PMID:17101203 | 2,3,7,8-Tetrachlorodibenzofuran | decreases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | 2-butoxyethanol | decreases expression | ISO | RGD:735675 | 6480464 | n-butoxyethanol results in decreased expression of B3GNT5 mRNA | CTD | PMID:19812364 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:735674 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of B3GNT5 mRNA | CTD | PMID:28628672 | 4,4'-sulfonyldiphenol | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of B3GNT5 mRNA | CTD | PMID:36041667 | aflatoxin B1 | affects expression | ISO | RGD:735674 | 6480464 | Aflatoxin B1 affects the expression of B3GNT5 protein | CTD | PMID:20106945 | all-trans-retinoic acid | increases expression | ISO | RGD:735674 | 6480464 | Tretinoin results in increased expression of B3GNT5 mRNA | CTD | PMID:33167477 | ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of B3GNT5 mRNA | CTD | PMID:16483693 | aristolochic acid A | decreases expression | ISO | RGD:735674 | 6480464 | aristolochic acid I results in decreased expression of B3GNT5 mRNA | CTD | PMID:33212167 | belinostat | decreases expression | ISO | RGD:735674 | 6480464 | belinostat results in decreased expression of B3GNT5 mRNA | CTD | PMID:26272509 | belinostat | multiple interactions | ISO | RGD:735674 | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA | CTD | PMID:27188386 | benzo[a]pyrene | increases expression | ISO | RGD:735675 | 6480464 | Benzo(a)pyrene results in increased expression of B3GNT5 mRNA | CTD | PMID:22228805 | benzo[b]fluoranthene | increases expression | ISO | RGD:735675 | 6480464 | benzo(b)fluoranthene results in increased expression of B3GNT5 mRNA | CTD | PMID:26377693 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of B3GNT5 mRNA | CTD | PMID:25181051 | bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of B3GNT5 mRNA | CTD | PMID:36041667 | bisphenol A | multiple interactions | ISO | RGD:735674 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of B3GNT5 mRNA | CTD | PMID:28628672 | bisphenol F | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of B3GNT5 mRNA | CTD | PMID:36041667 | buta-1,3-diene | decreases expression | ISO | RGD:735675 | 6480464 | 1, 3-butadiene results in decreased expression of B3GNT5 mRNA | CTD | PMID:29038090 | carbon nanotube | increases expression | ISO | RGD:735675 | 6480464 | Nanotubes, Carbon results in increased expression of B3GNT5 mRNA | CTD | PMID:25554681 | chloroprene | decreases expression | ISO | RGD:735675 | 6480464 | Chloroprene results in decreased expression of B3GNT5 mRNA | CTD | PMID:23125180 | chlorpyrifos | increases expression | ISO | RGD:735675 | 6480464 | Chlorpyrifos results in increased expression of B3GNT5 mRNA | CTD | PMID:34289071 | cisplatin | increases expression | ISO | RGD:735674 | 6480464 | Cisplatin results in increased expression of B3GNT5 mRNA | CTD | PMID:27594783 | cisplatin | multiple interactions | ISO | RGD:735674 | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of B3GNT5 mRNA | CTD | PMID:27392435 | cisplatin | decreases expression | ISO | RGD:735674 | 6480464 | Cisplatin results in decreased expression of B3GNT5 mRNA | CTD | PMID:27392435 | clorgyline | increases expression | ISO | RGD:735674 | 6480464 | Clorgyline results in increased expression of B3GNT5 mRNA | CTD | PMID:19691856 | copper atom | multiple interactions | ISO | RGD:735674 | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of B3GNT5 mRNA | CTD | PMID:20971185 | copper(0) | multiple interactions | ISO | RGD:735674 | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of B3GNT5 mRNA | CTD | PMID:20971185 | coumestrol | decreases expression | ISO | RGD:735674 | 6480464 | Coumestrol results in decreased expression of B3GNT5 mRNA | CTD | PMID:19167446 | coumestrol | multiple interactions | ISO | RGD:735674 | 6480464 | [Coumestrol co-treated with 2 more ... | CTD | PMID:19167446 | crocidolite asbestos | increases expression | ISO | RGD:735674 | 6480464 | Asbestos, Crocidolite results in increased expression of B3GNT5 mRNA | CTD | PMID:18687144 | crocidolite asbestos | affects expression | ISO | RGD:735674 | 6480464 | Asbestos, Crocidolite affects the expression of B3GNT5 mRNA | CTD | PMID:25757056 | cyclosporin A | increases expression | ISO | RGD:735674 | 6480464 | Cyclosporine results in increased expression of B3GNT5 mRNA | CTD | PMID:20106945 | dexamethasone | multiple interactions | ISO | RGD:735674 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of B3GNT5 mRNA | CTD | PMID:28628672 | dimethylarsinic acid | multiple interactions | ISO | RGD:735675 | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of B3GNT5 mRNA | CTD | PMID:34876320 | dorsomorphin | multiple interactions | ISO | RGD:735674 | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | RGD:735674 | 6480464 | Doxorubicin results in decreased expression of B3GNT5 mRNA | CTD | PMID:29803840 | endosulfan | decreases expression | EXP | | 6480464 | Endosulfan results in decreased expression of B3GNT5 mRNA | CTD | PMID:29391264 | Enterolactone | multiple interactions | ISO | RGD:735674 | 6480464 | [Coumestrol co-treated with 2, 3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of B3GNT5 mRNA | CTD | PMID:19167446 | entinostat | decreases expression | ISO | RGD:735674 | 6480464 | entinostat results in decreased expression of B3GNT5 mRNA | CTD | PMID:26272509 | entinostat | multiple interactions | ISO | RGD:735674 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA | CTD | PMID:27188386 | fenvalerate | increases expression | EXP | | 6480464 | fenvalerate results in increased expression of B3GNT5 mRNA | CTD | PMID:30307764 | formaldehyde | increases expression | ISO | RGD:735674 | 6480464 | Formaldehyde results in increased expression of B3GNT5 mRNA | CTD | PMID:23649840, PMID:27664576 | hydrogen peroxide | affects expression | ISO | RGD:735674 | 6480464 | Hydrogen Peroxide affects the expression of B3GNT5 mRNA | CTD | PMID:20044591 | indometacin | multiple interactions | ISO | RGD:735674 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of B3GNT5 mRNA | CTD | PMID:28628672 | lead(0) | affects expression | ISO | RGD:735674 | 6480464 | Lead affects the expression of B3GNT5 mRNA | CTD | PMID:28903495 | lead(2+) | affects expression | ISO | RGD:735674 | 6480464 | Lead affects the expression of B3GNT5 mRNA | CTD | PMID:28903495 | melphalan | increases expression | ISO | RGD:735674 | 6480464 | Melphalan results in increased expression of B3GNT5 mRNA | CTD | PMID:22363485 | methyl methanesulfonate | increases expression | ISO | RGD:735674 | 6480464 | Methyl Methanesulfonate results in increased expression of B3GNT5 mRNA | CTD | PMID:23649840 | methylarsonic acid | multiple interactions | ISO | RGD:735675 | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of B3GNT5 mRNA | CTD | PMID:34876320 | methylisothiazolinone | increases expression | ISO | RGD:735674 | 6480464 | 2-methyl-4-isothiazolin-3-one results in increased expression of B3GNT5 mRNA | CTD | PMID:31629900 | nickel sulfate | increases expression | ISO | RGD:735674 | 6480464 | nickel sulfate results in increased expression of B3GNT5 mRNA | CTD | PMID:22714537 | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of B3GNT5 mRNA | CTD | PMID:33387578 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | RGD:735675 | 6480464 | [perfluorooctane sulfonic acid co-treated with Pectins] results in increased expression of B3GNT5 mRNA | CTD | PMID:36331819 | phenobarbital | affects expression | ISO | RGD:735674 | 6480464 | Phenobarbital affects the expression of B3GNT5 mRNA | CTD | PMID:19159669 | pirinixic acid | increases expression | ISO | RGD:735675 | 6480464 | pirinixic acid results in increased expression of B3GNT5 mRNA | CTD | PMID:25270620 | potassium chromate | decreases expression | ISO | RGD:735674 | 6480464 | potassium chromate(VI) results in decreased expression of B3GNT5 mRNA | CTD | PMID:22714537 | progesterone | increases expression | ISO | RGD:735674 | 6480464 | Progesterone results in increased expression of B3GNT5 mRNA | CTD | PMID:21795739 | resveratrol | multiple interactions | ISO | RGD:735674 | 6480464 | [Coumestrol co-treated with resveratrol] results in decreased expression of B3GNT5 mRNA | CTD | PMID:19167446 | SB 431542 | multiple interactions | ISO | RGD:735674 | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | serpentine asbestos | increases expression | ISO | RGD:735674 | 6480464 | Asbestos, Serpentine results in increased expression of B3GNT5 mRNA | CTD | PMID:24160326 | silicon dioxide | increases expression | ISO | RGD:735674 | 6480464 | Silicon Dioxide analog results in increased expression of B3GNT5 mRNA | CTD | PMID:25895662 | sodium arsenate | multiple interactions | ISO | RGD:735675 | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of B3GNT5 mRNA | CTD | PMID:34876320 | sodium arsenite | multiple interactions | ISO | RGD:735675 | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of B3GNT5 mRNA | CTD | PMID:34876320 | sodium arsenite | increases expression | ISO | RGD:735675 | 6480464 | sodium arsenite results in increased expression of B3GNT5 mRNA | CTD | PMID:36209798 | sulforaphane | increases expression | ISO | RGD:735674 | 6480464 | sulforaphane results in increased expression of B3GNT5 mRNA | CTD | PMID:31838189 | sunitinib | decreases expression | ISO | RGD:735674 | 6480464 | Sunitinib results in decreased expression of B3GNT5 mRNA | CTD | PMID:31533062 | toluene | increases expression | ISO | RGD:735674 | 6480464 | Toluene results in increased expression of B3GNT5 mRNA | CTD | PMID:28245982 | topotecan | increases expression | EXP | | 6480464 | Topotecan results in increased expression of B3GNT5 mRNA | CTD | PMID:25729387 | trichostatin A | decreases expression | ISO | RGD:735674 | 6480464 | trichostatin A results in decreased expression of B3GNT5 mRNA | CTD | PMID:24935251 | valproic acid | affects expression | ISO | RGD:735674 | 6480464 | Valproic Acid affects the expression of B3GNT5 mRNA | CTD | PMID:25979313 | valproic acid | decreases expression | ISO | RGD:735674 | 6480464 | Valproic Acid results in decreased expression of B3GNT5 mRNA | CTD | PMID:23179753 more ... | vinclozolin | increases expression | EXP | | 6480464 | vinclozolin results in increased expression of B3GNT5 mRNA | CTD | PMID:23034163 | vincristine | increases expression | ISO | RGD:735674 | 6480464 | Vincristine results in increased expression of B3GNT5 mRNA | CTD | PMID:23649840 | zinc atom | multiple interactions | ISO | RGD:735674 | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of B3GNT5 mRNA | CTD | PMID:18593933 | zinc(0) | multiple interactions | ISO | RGD:735674 | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of B3GNT5 mRNA | CTD | PMID:18593933 | |